Financing ·
CAMP4 Therapeutics closed the second tranche of its private placement on August 3, 2026, generating approximately…
CAMPCamp4 Therapeutics Corp
CAMP4 Therapeutics closed the second tranche of its private placement on August 3, 2026, generating approximately $50.1 million in gross proceeds. The company issued 10,756,498 shares of common stock at $1.53 per share and 21,925,368 pre-funded warrants at $1.5299 each. Management and directors also purchased an additional 39,306 shares at $1.65 per share. This closing was triggered by regulatory clearance from Australia’s Therapeutic Goods Administration for the Phase 1/2 trial of CMP-002. The total private placement raised approximately $100 million across two closings. CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics to treat genetic diseases.